substances and inefficacious products, but from the threat posed by counterfeit and substandard products.
A third pointer to a registration-policy disconnect is the licensing of artemisinin-based monotherapies. In recent years, there has been a shift towards combination therapy in malaria to reduce the rate at which resistance develops (Hastings 2001) . The WHO now strongly discourages the use of monotherapy for first-line antimalarial drug therapy, and instead advocates 'Artemisinin-based Combination Therapy' (ACT) to try to stem the spread of drug-resistance. Accordingly, Kenya recently changed its policy from sulfadoxine/ sulfamethoxypyrazine-pyrimethamine (which, in this context, is a 'monotherapy') to artemether-lumefantrine, an ACT (MoH 2004). But there is concern that the continued availability and use of artemisinin monotherapies may encourage parasite resistance and undermine the effectiveness of ACT in Kenya. In January 2006 the World Health Organization called on local and international manufacturers of artemisinin monotherapies to withdraw such products from African markets voluntarily. Some manufacturers such as Cipla of India have responded positively, but others have not (http://www.un.org/apps/news/ story.asp?NewsID=18437&Cr=malaria&Cr1=, accessed 17/05/06). In Kenya, as in other countries, drugs are registered on the basis of safety, quality, and efficacy and not on the basis of 'need'. This means that artemisinin monothereapies currently on the market are there legally even though they are deemed to be a threat to the new first-line antimalarial drug policy. In the short term, the Kenyan regulator, the Pharmacy and Poisons Board (PPB), could encourage manufacturers to 1) phase out their products voluntarily and give a grace period over which this can be achieved, and 2) not submit new artemisinin or any other antimalarial monotherapy for registration. If this does not work, in the medium-long term, a change in legislation will be needed to give the PPB the mandate to withdrawn these products from the market.
A number of other strategies could bridge the gap between registration and antimalarial drug policy in Kenya. The most obvious is the inclusion of malaria experts in the evaluation of antimalarial product dossiers submitted for drug registration. A complementary approach to this is greater participation of PPB, and professional pharmacy bodies such as the Pharmaceutical Society of Kenya in the Working Groups where policy options for malaria are debated. Greater participation in policy discussion on malaria will extend the PPB's role in antimalarial drug policy changes from only registering products for the market, as if this were an end in itself, to looking at the wider public health impact of deciding whether to register a given product or not.
The consequences of ineffective drug regulation for malaria are many. Antimalarial drugs are consumed by millions of very poor people each year (Snow et al. 2003) , and inadequate treatment can rapidly lead to death in those who have yet to develop any clinical immunity (Greenwood et al. 1987) . Protecting the future of new medicines, like artemisinin derivatives, from the threat posed by widespread inappropriate use is a global responsibility (IOM 2004) . We believe that monitoring the effectiveness of drug regulation regionally and globally is just as important as the monitoring of drug efficacy or parasite resistance. Countries will need help in improving each step of drug regulation, legislation and operations. An international call to ban medicines will only be effective to the extent that countries have the political will and the means to implement it. Amin et al. Page 4 Table 1 Ineffective ( 
